000			03427nam a22003015i 4500
001			402908
003			ES-MaUEC
005			20240528105941.0
007			cr nn 008mamaa
008			231231s2023 sz | o |||| 0|eng d
020			_a9783031399442
024	7		_a10.1007/978-3-031-39944-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC254-282 _b2023 EB
245	0	0	_aImmune Strategies for Gastrointestinal Cancer _cedited by Markus Moehler, Friedrich Foerster
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCancer Immunotherapy _x2662-8392 ; _v2
505	0		_aPart I Role of the Tumor Microenvironment -- An Overview of the Tumor Microenvironment and Response to Immunotherapy in Gastrointestinal Malignancies -- Part II Esophagus -- Approach to Immunotherapy in Oesophageal Cancer -- Perspective on the Immunotherapy of Esophageal Cancer -- Part III Stomach -- Immunotherapy of Gastric Cancer: Focus on Perioperative Strategies -- Stomach: The Standard of Care {plusmn} HER2 -- Perspective on the Immunotherapy of Gastric Cancer -- Part IV Colon -- Immunotherapy in dMMR/MSI-H Colon Cancer -- Immunotherapy in the Treatment of Advanced Colorectal Cancer -- Immunotherapy of Rectal Cancer -- Perspective on Immunotherapy of Colon Cancer: Challenges for the Future -- Part V HCC -- Immune Strategies for Gastrointestinal Cancer: HCC -- Immunotherapy in GI Cancers: Hepatocellular Carcinoma: Perspective -- Part VI Biliary Tract -- Immunotherapy of Biliary Tract Cancer -- Perspective on Immunotherapy Use in Biliary Tract Cancer -- Part VII Pancreas -- Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective -- Perspective on the Immunotherapy of Pancreatic Cancer -- Part VIII Biomarkers for Immunotherapy in Gastrointestinal Cancers -- Biomarkers for Immunotherapy in Gastrointestinal Cancers.
520			_aThis book provides an overview of the available evidence surrounding immunotherapy in gastrointestinal cancers, and discusses its future place in clinical practice. Immunotherapy has celebrated some astonishing therapeutic successes in a variety of cancer types and is becoming increasingly relevant in daily clinical practice. Currently, the predominant class of immunotherapeutic drugs is the so-called checkpoint inhibitors, which disengage the physiological brakes on the immune system, enabling a more effective anti-cancer immune response. Malignancies of the gastrointestinal tract, which account for the majority of cancer cases worldwide, are a major cause of morbidity and mortality, creating an urgent need for more effective therapies. A large number of clinical trials have evaluated the efficacy of cancer immunotherapy in gastrointestinal malignancies and demonstrated its potential in certain subsets of patients. This book will appeal to a wide readership, including oncologists, health care professionals in general and biomedical scientists.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-39944-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_Medicine_2023
999			_c402908 _d402908